LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

Home・Listă Acțiuni・Puma Biotechnology Inc

Puma Biotechnology Inc

Deschisă

SectorSănătate

6.94 0.14

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

6.82

Maxim

7.08

Indicatori cheie
By Trading Economics
Venit	-16M -3.8M
Vânzări	-31M 45M
P/E Medie Sector	14.75 50.102
EPS	-0.04
Marjă de profit	-8.375
Angajați	179
EBITDA	-28M -1.3M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-30.26% downside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-23M 360M
Deschiderea anterioară	6.8
Închiderea anterioară	6.94

Sentimentul știrilor

By Acuity

38%

62%

103 / 344 Clasament în Healthcare

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 iun. 2026, 23:38 UTC

Achiziții, Fuziuni, Preluări

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 iun. 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 iun. 2026, 22:08 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 iun. 2026, 21:55 UTC

Achiziții, Fuziuni, Preluări

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 iun. 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 iun. 2026, 21:22 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 iun. 2026, 20:46 UTC

Achiziții, Fuziuni, Preluări

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 iun. 2026, 20:22 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Declares $11 Special Div

1 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 iun. 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 iun. 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 iun. 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 iun. 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 iun. 2026, 18:54 UTC

Achiziții, Fuziuni, Preluări

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 iun. 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 iun. 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 iun. 2026, 18:00 UTC

Achiziții, Fuziuni, Preluări

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 iun. 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 iun. 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 17:10 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-30.26% jos

Prognoză pe 12 luni

Medie 5 USD -30.26%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Puma Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

103 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.